statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eledon Pharmaceuticals, Inc. (ELDN) has disclosed a new risk, in the Share Price & Shareholder Rights category. Eledon Pharmaceuticals, Inc. faces...

Eledon Pharmaceuticals Risks Shareholder Equity Dilution Amidst Private Placement and Potential Stock Issuances

In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Eledon Pharmaceuticals (ELDN Research Report), with a p...

Eledon Pharmaceuticals: A Strong Buy on the Back of Promising Clinical Trials and a Solid Financial Footing

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Eledon Pharmaceuticals reports Q4 EPS (32c), consensus (39c)

Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection Tegoprubart used as a component of the immunosuppressive treatment regimen following...

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

IRVINE, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ( Eledon ) (NASDAQ: ELDN) today announced the enrollment of the 12th participant on March 23, 2024, in the Company's...

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Eledon Pharmaceuticals (NASDAQ:ELDN  Get Free Report)s stock had its buy rating reissued by analysts at HC Wainwright in a note issued to investors on Friday, Benzinga...

Eledon Pharmaceuticals (NASDAQ:ELDN) Rating Reiterated by HC Wainwright

Historic kidney xenotransplantation procedure conducted at Massachusetts General Hospital Tegoprubart administration has now been used investigationally to prevent rejection in both kidney and heart...

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

Armistice Capital LLC decreased its position in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN  Free Report) by 1.0% during the 3rd quarter, according to the company in its most recent...

Armistice Capital LLC Has $2.50 Million Stock Holdings in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)

IRVINE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ( Eledon ) (NASDAQ: ELDN) today announced that the Company's Compensation Committee granted 42,500 restricted stock...

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN  Free Report)  Equities research analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for Eledon Pharmaceuticals...

Eledon Pharmaceuticals, Inc. to Post Q1 2024 Earnings of ($0.33) Per Share, Leerink Partnrs Forecasts (NASDAQ:ELDN)

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. Eledon Pharmaceuticals was founded on March 26, 2004 and is headquartered in Irvine, CA.

Volume	9,187.00
52-Wk High	$2.95
52-Wk Low	$1.07

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.37	--	--	N/A
Q4'23	-$0.40	-$0.32	20.50%	BEAT
Q3'23	-$0.46	-$0.35	23.99%	BEAT
Q2'23	-$0.46	-$0.40	12.81%	BEAT
Q1'23	-$0.64	-$0.75	-17.91%	MISSED

ELDN Eledon Pharmaceuticals Inc

About

Feed

News

Earnings

Fundamentals